Topicals, generic [Regulatives / Guidelines]

posted by The Outlaw Torn – Europe, 2013-04-01 10:03 (4829 d 01:05 ago) – Posting: # 10319
Views: 28,327

Good morning folks,

It seems the new guideline hasn't removed the need to conduct a BE study (for safety reasons) for opthalmic solutions that may contain an ingredient that is absorbed systemically. Has anyone successfully argued against this? It appears it's still fine to obtain a biowaiver for the efficacy part, but not for safety?! To me, this is a WTF moment, but maybe I'm missing out on something. Does that make sense to anyone (for a solution)?

Thank you,
Outlaw

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
125 visitors (0 registered, 125 guests [including 11 identified bots]).
Forum time: 11:09 CEST (Europe/Vienna)

Science is simply common sense at its best that is,
rigidly accurate in observation, and
merciless to fallacy in logic.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5